BUSINESS
Despite strong run, pharma and healthcare stocks still have some steam left, says Chirag Dagli of DSP MF
According to Dagli, the strong growth trajectory expected of the sector also supports its valuation metrics. He also expects the various segments within the pharma and healthcare space to perform well in the near term.
BUSINESS
Will the dollar index usher in a bull run in Indian markets?
There is anticipation that the dollar index will stay within the 100-mark, bringing FII inflows into India and propping up the markets.
BUSINESS
Is 2023 going to be the stellar season for IPOs?
A vibrant secondary market often enhances the allure of the primary market, as more investors are likely to bid for new issues when the overall sentiment is upbeat. Analysts cited this factor as a major trigger for the rise in the number of IPOs hitting the Street since March.
BUSINESS
With roadblocks out of the way, is Lupin finally on the growth path?
The growing positivity around Lupin is clearly demonstrated in the stock’s performance, which has spiked over 38 percent since the start of April. However, some analysts believe the valuation is a bit stretched.
BUSINESS
A healthy love affair continues as healthcare stocks remain MF darlings
Ten out of 11 mutual fund houses covered by Nuvama Alternative & Quantitative Research have gone overweight on pharma and healthcare, as against their weightage in Nifty 200.
BUSINESS
Paint makers in blues as surge in crude oil may jack up input costs
Even though most brokerages had predicted some margin recovery for paint companies in Q1, the trends of rising input costs and increasing competition may soon water down those expectations.
BUSINESS
Indian pharma market records a blip, but stays the course for fresh rally
A delayed monsoon and reduced demand for acute products impacted the industry briefly, but analysts expect the sector to sustain double-digit growth figures for the year.
BUSINESS
Healthcare sector on robust growth path; here's why
Demand for wellness, better health awareness and greater access to medical facilities will drive the growth of all players in the healthcare industry and associated sectors.
BUSINESS
Pipeline Check: Here are the blockbuster drugs lined up by Indian drugmakers for US launch
Cipla is rolling out plans to launch a generic of Advair while Lupin has got approval for Spiriva
BUSINESS
Why is Indian pharma failing to meet US standards?
It’s not as if domestic manufacturing has suddenly become sloppy. A closer look will reveal the strides made by Indian pharma firms as they attempt to break into the complex drugs space, which attracts higher scrutiny.
BUSINESS
F&O Manual: New day, new high for Nifty, but traders sound caution as day progresses
Gains for five straight sessions have triggered some caution among traders as they now anticipate profit booking to kick in. However, the bullish sentiment persists as they also foresee a decline in the market to be bought out.
BUSINESS
Can Nifty sustain its mojo in July F&O series? Here's what rollovers say
Net longs of FIIs stood at 56,000 contracts, up from 19,000 at the beginning of the previous series. Experts believe the momentum can take the markets higher to 19,300 for the Nifty 50 with continued sectoral rotations.
BUSINESS
Jefferies positive on Mankind Pharma's growth prospects but valuations remain a sore point
Aside from valuations, Jefferies remains bullish on Mankind's strong future prospects, thanks to its well-diversified portfolio and consistent track record of outperforming market growth.
BUSINESS
Can Indian chemicals companies stand strong against global demand concerns?
Inventory destocking by customers and weak global demand may keep volumes margins depressed for the short term, say brokerages.
BUSINESS
What's on offer: What does buying stake in Mylab mean for Zydus?
Analysts predict the partial acquisition is a stepping stone for the company to venture into the diagnostic space at a later stage.
BUSINESS
The big picture: Are Ipca's regulatory woes actually a negative?
Some analysts believe the inspections at Ipca's manufacturing facilities may give the company a second chance to turn things around and get rid of the import alerts.
BUSINESS
Mid-sized hospitals can deliver outsized returns
Growing demand on the back of rising disposable income, improved healthcare penetration, expansion into tier II cities, and an improved case and payor-mix are factors that will fuel the next leg of growth for hospital companies
BUSINESS
Lupin's much-awaited approval for gSpiriva is here; will it change the drug maker’s fortunes?
The market has cheered the development, which comes ahead of the timeline set by Lupin's management at its March quarter earnings call, much more needs to be done before the company's fortunes turn around meaningfully.
BUSINESS
Who's winning the game in the Indian pharma market?
While acute therapies account for a higher share in the Indian pharma market, the chronic segment catching up at a higher speed
BUSINESS
Is the pharma sector on the road to regaining its mojo?
Analysts believe fresh investments in R&D, the widespread China+1 sentiment, and the government's push for the sector through the PLI scheme and tighter regulations could work in favour of the domestic pharma sector.
BUSINESS
HDFC Sec sees 10% upside potential in Rainbow Children's Medicare, here's why the optimism
Recently, leading life insurance firms also raked up their stakes in Rainbow Children's Medicare in May through investments of around Rs 161 crore.
BUSINESS
Indian Pharma Market records strong growth for second straight month in May
Indian drugmakers outperformed multinational pharma players in the Indian Pharma Market in May, a trend that has been going on since the past 12 months.
BUSINESS
Several large block deals in Axis Bank; Bain Capital likely seller
Bain Capital held a 1.3 percent stake in Axis Bank through its fund BC Asia Investments VII as on March 31, 2023.
BUSINESS
Mankind, P&G and Alkem shine as healthcare stocks grab biggest pie of MF investments in May
Max Healthcare, Narayana Hrudayalaya and Ajanta Pharma from the small and mid-cap space saw selling, following their strong run during May.
